Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

Cannot have received: lurbinectedin (lurbinectedin)

Received prior treatment with lurbinectedin

Cannot have received: trabectedin (trabectedin)

Received prior treatment with trabectedin

Cannot have received: investigational product

Exception: Observational studies are permitted

Received prior treatment with any investigational product within 4 weeks of first infusion of study intervention. Observational studies are permitted.

Cannot have received: live or live attenuated vaccine

Exception: Inactive and mRNA vaccines allowed

Received live or live attenuated vaccines within 4 weeks of the first dose of study treatment or plans to receive live vaccines during study participation. Administration of inactive vaccines or messenger ribonucleic acid (mRNA) vaccines (for example, inactivated influenza vaccines or COVID-19 vaccines) are allowed.

Cannot have received: major surgery

Exception: unless fully recovered

Had major surgery ≤ 4 weeks or radiation therapy ≤ 2 weeks prior to enrollment unless fully recovered. Prior palliative radiotherapy is permitted, provided it was completed at least 2 weeks prior to participant enrollment.

Cannot have received: radiation therapy

Exception: Prior palliative radiotherapy permitted if completed ≥ 2 weeks prior to enrollment

Had major surgery ≤ 4 weeks or radiation therapy ≤ 2 weeks prior to enrollment unless fully recovered. Prior palliative radiotherapy is permitted, provided it was completed at least 2 weeks prior to participant enrollment.

Cannot have received: allogeneic bone marrow transplantation

Received prior allogeneic bone marrow transplantation

Cannot have received: solid organ transplant

Received prior solid organ transplant

Cannot have received: chemotherapy

Received chemotherapy ≤ 3 weeks prior to start of study intervention.